This protocol covers the management of hypopituitarism presenting as central hypogonadism in a premenopausal female patient with no contraindications to treatment.
Premenopausal female with central hypogonadism and no contraindications. Current evidence-based guidance recommends gonadal hormone treatment in this population.
Gonadal hormone replacement is the recommended intervention for this scenario — the appropriate preparation depends on individual anatomical and clinical factors reviewed in the full protocol.
DOI: 10.1210/jc.2016-2118
We recommend gonadal hormone treatment in premenopausal women with central hypogonadism, provided there are no contraindications.
For premenopausal women with central hypogonadism, clinicians should prescribe gonadal hormone replacement (unopposed estrogens for women who have undergone hysterectomy, or combined estrogen-progestogen preparations for those with an intact uterus to prevent endometrial hyperplasia).